Osteopontina como marcador de resposta à radioterapia e quimioterapia em pacientes com câncer de cabeça e pescoço localmente avançado / Osteopontin as a marker of response to chemotherapy and radiotherapy in patients with locally advanced head and neck cancer
AUTOR(ES)
Glauber Moreira Leitão
DATA DE PUBLICAÇÃO
2008
RESUMO
INTRODUCTION: Osteopontin (OPN) is a glycoprotein present in tissues and body fluids involved in several pathological processes that include inflammation, cell proliferation, invasion of the extracellular matrix, tumor progression and metastasis. In head and neck squamous cell carcinoma (HNSCC) patients, OPN has been associated with greater tumor aggressiveness and used as a prognostic marker. We investigated the prognostic and predictive value of plasma OPN in homogeneously treated (HNSCC) patients. METHODS: Longitudinal prospective study of 47 patients with locally advanced and inoperable HNSCC treated with exclusive platin based concomitant chemoradiotherapy. Plasma OPN was determined by ELISA (n=14 kit I, n=32 kit II) pre and postreatment and correlated with tumor response, overall survival (OS) and progression-free survival (PFS). RESULTS: Median OPN levels in ng/ml were 2,1 and 1,9 pre and postreatment, respectively, by kit I and 69,5 and 87,9 by kit II. Patients were categorized as OPN low or high, using the median as a cut-off point. Patients with oropharynx tumors, as compared to other subsites, were more frequently categorized as low OPN (p = 0,03). A low postreatment OPN level was associated with tumor response (p = 0,06) and a high postreatment OPN level was associated with poor PFS, 11.9 vs. 14.5 months (p=0.09, log rank). Mean OS was 16.2 and 13.7 months in low and high postreatment OPN pts, respectively (p=0.10, log rank). CONCLUSIONS: In this group of HNSCC patients, it is suggested that a low plasma OPN after chemoradiotherapy is associated with a lower response rate and a worse PFS.
ASSUNTO(S)
osteopontin neoplasias de cabeça e pescoço chemoradiotherapy osteopontina head and neck cancer quimioterapia squamous cell carcinoma radioterapia neoplasias de células escamosas
Documentos Relacionados
- Mucosite oral em pacientes portadores de câncer de cabeça e pescoço submetidos à radioterapia e quimioterapia concomitantes.
- Alterações Orais Tardias em Pacientes Submetidos a Radioterapia e/ou Quimioterapia em Cabeça e Pescoço.
- Estudo de fase I/II de Erlotinib (OZI-774) combinado com radioterapia e cisplatina em pacientes com carcinoma epidermóide de cabeça e pescoço, localmente avançado
- Impacto orofacial da radioterapia de cabeça e pescoço
- Avaliação da expressão da proteína EZH2 na resposta do carcinoma de mama localmente avançado à quimioterapia neoadjuvante